48,460
edits
Difference between revisions of "Ancillary testing in prostate cancer"
Jump to navigation
Jump to search
Ancillary testing in prostate cancer (view source)
Revision as of 15:18, 1 November 2022
, 15:18, 1 November 2022no edit summary
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
Molecular panel: | Molecular panel: | ||
*BRCA1 | *[[BRCA1]]. | ||
*BRCA2 | *[[BRCA2]]. | ||
*ATM | *ATM. | ||
*PALB2 | *PALB2. | ||
==MMR testing== | |||
*MMR deficiency is seen in approximately 3% of prostate cancers.<ref>{{cite journal |authors=Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI |title=Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade |journal=JAMA Oncol |volume=5 |issue=4 |pages=471–478 |date=April 2019 |pmid=30589920 |pmc=6459218 |doi=10.1001/jamaoncol.2018.5801 |url=}}</ref> | |||
==See also== | ==See also== | ||